What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
What key factors will you consider when selecting patients for this therapy?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Obinutuzumab for Lupus Nephritis
Community PollStarted
What are your barriers to prescribing obinutuzumab for lupus nephritis?
70 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)
Answered on
1. Insurance Coverage: Oh, easy one! Since it is not FDA-approved yet for lupus nephritis (I bet it will be though... great data so far), insurance will unlikely cover it, except for a few (like Tricare, which is sometimes easier to get off-label drugs).
I am fortunate to have the NIH Lupus Center c...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Rheumatology · University of Alabama Birmingham
Answered on
Approximately 50% of the time in my clinical practice, when prescribing Obinutuzumab, insurance companies prefer to cover Rituximab or its biosimilars instead. With the latest data from the REGENCY trial, I am now more hesitant to use Obinutuzumab due to the higher risk of infections—primarily COVID...
Join for free or sign in to see the full answer